{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:35:34Z","timestamp":1792787734525,"version":"4.5.0"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Jiangsu Xiansheng Pharmaceutical Co., Ltd. National Key Laboratory of Neurological and Tumor Drug Research and Developmen","award":["SKLSIM-F-2025243"],"award-info":[{"award-number":["SKLSIM-F-2025243"]}]},{"name":"Joint Research Fund Project of the Academy of Medical Sciences","award":["2023GLLH0131"],"award-info":[{"award-number":["2023GLLH0131"]}],"id":[{"id":"https:\/\/ror.org\/00c489v88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of HER2-targeted tyrosine kinase inhibitors (TKIs) in patients with HER2-positive advanced or locally advanced breast cancer using a Bayesian network meta-analysis and to provide comparative evidence for individualized treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched for randomized controlled trials evaluating HER2-targeted TKIs in patients with HER2-positive advanced or locally advanced breast cancer. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) were assessed as efficacy outcomes, while treatment-related adverse events were evaluated as safety outcomes. A Bayesian network meta-analysis was performed using R (version 4.2.2) and Stata (version 16.0). Treatments were ranked according to the surface under the cumulative ranking curve (SUCRA). The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO: CRD420250650274).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen randomized controlled trials involving 5,289 patients were included. According to SUCRA rankings, pyrotinib plus capecitabine (Pyrotinib_C) showed the highest probability of favorable ranking PFS, ORR, and DCR. Tucatinib combined with trastuzumab and capecitabine (Tucatinib_T_C) demonstrated the highest probability of favorable OS ranking. Regarding safety, pyrotinib combined with trastuzumab and capecitabine (Pyrotinib_T_C) was associated with the highest incidence of serious adverse events, diarrhea, and hand-foot syndrome, whereas Pyrotinib_C showed the highest incidence of anemia and lapatinib plus capecitabine (Lapatinib_C) demonstrated the highest incidence of rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among currently available HER2-targeted TKIs, Pyrotinib_C showed the highest probability of favorable ranking for PFS and tumor response outcomes, whereas Tucatinib_T_C showed the highest probability of favorable OS ranking. However, pyrotinib-containing regimens were associated with a higher risk of treatment-related toxicities. These findings highlight the importance of balancing efficacy and safety when selecting HER2-targeted TKI therapies and support individualized treatment strategies for patients with HER2-positive advanced breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795549261489524","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:49:56Z","timestamp":1789516196000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety Ranking of HER2-Targeted TKIs in Advanced Breast Cancer: A Bayesian Network Meta-Analysis"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6706-0091","authenticated-orcid":false,"given":"Rongjie","family":"Li","sequence":"first","affiliation":[{"name":"Inner Mongolia Medical University"},{"name":"Peking University Cancer Hospital Inner Mongolia Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huangfu","sequence":"additional","affiliation":[{"name":"Inner Mongolia Medical University"},{"name":"Peking University Cancer Hospital Inner Mongolia Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lan","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Inner Mongolia Medical University"},{"name":"Peking University Cancer Hospital Inner Mongolia Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Hou","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital Inner Mongolia Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaodong","family":"Ping","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital Inner Mongolia Hospital"},{"name":"Peking University Cancer Hospital & Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_7_3_2","first-page":"1634","article-title":"4th ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Ann","volume":"29","author":"Cardoso F","year":"2022","unstructured":"Cardoso F, Senkus E, Costa A, et al. 4th ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Ann. Oncol. 2022;29:1634-1657.","journal-title":"Oncol"},{"key":"e_1_3_7_4_2","first-page":"1","article-title":"Systemic Therapy for HER-2-Positive Metastatic Breast Cancer: Moving Into a New Era","volume":"42","author":"Gion M","year":"2022","unstructured":"Gion M, Trapani D, Cort\u00e9s A, et al. Systemic Therapy for HER-2-Positive Metastatic Breast Cancer: Moving Into a New Era. Am Soc Clin Oncol Educ Book. 2022;42:1-11.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.05.004"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413513"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210477"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30702-6"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.09.014"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00147"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-159"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184.ch2"},{"key":"e_1_3_7_15_2","first-page":"80","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef G","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. ResSynth Methods. 2016;7:80-93.","journal-title":"ResSynth Methods"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.005"},{"issue":"392","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"e087259","DOI":"10.1136\/bmj-2025-087259","article-title":"Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial","volume":"16","author":"Ma F","year":"2026","unstructured":"Ma F, Yan M, Li W, et al. Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial. BMJ. 2026;16(392):e087259.","journal-title":"BMJ"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-20-25"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.9590"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2020.06.003"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70397-7"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.04.010"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.1794"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5241"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.2578"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064320"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0618-z"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0181"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0237"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5149"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0636"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.01.021"},{"key":"e_1_3_7_33_2","first-page":"423","article-title":"Advances in Targeted Therapy for Brain Metastases in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Focus on ADCs and TKIs","volume":"17","author":"Rao B","year":"2025","unstructured":"Rao B, Huo P, Lu J, Huang W. Advances in Targeted Therapy for Brain Metastases in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Focus on ADCs and TKIs. Breast Cancer (Dove Med Press). 2025;17:423-432.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0302"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70611"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70130-X"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat9773"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0349"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016140108"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549261489524","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795549261489524","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549261489524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:20:22Z","timestamp":1789716022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795549261489524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["10.1177\/11795549261489524"],"URL":"https:\/\/doi.org\/10.1177\/11795549261489524","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"11795549261489524"}}